Gram-positive infections are a major burden on patients and healthcare systems globally, and the need to treat these infections correctly in an empirical manner has become paramount. Further complicating this changing etiology is the emergence of resistant strains which are no longer predictably susceptible to standard first-line antimicrobials...
-
2003 (v1)PublicationUploaded on: April 14, 2023
-
2014 (v1)Publication
Urinary tract infections are one of the most common reasons for antimicrobial prescriptions, however urine cultures are often unavailable and the choice of antibiotics is therefore empiric. The ideal antimicrobial agent must have specific pharmacokinetic and pharmacodynamic characteristics and an adequate spectrum of activity in order to obtain...
Uploaded on: April 14, 2023 -
2022 (v1)Publication
No description
Uploaded on: October 27, 2024 -
2023 (v1)Publication
No description
Uploaded on: October 30, 2024 -
2019 (v1)Publication
No description
Uploaded on: October 30, 2024 -
2024 (v1)Publication
Wagenlehner and colleagues 1 demonstrated non-inferiority and superiority with respect to a primary endpoint of composite success (microbiological plus clinical) of cefepime/taniborbactam vs. meropenem in treating complicated urinary tract infections and acute pyelonephritis caused by carbapenem-susceptible gram-negative bacteria in adults. A...
Uploaded on: October 30, 2024 -
2022 (v1)Publication
Purpose of review: Acute bacterial skin and skin structure infections (ABSSSI) are a leading cause of morbidity, with a considerable variety of clinical presentation and a wide range of etiological pathogens. Of importance, the spread of multidrug-resistant (MDR) strains (i.e. methicillin-resistant Staphylococcus aureus or Gram-negative...
Uploaded on: April 14, 2023 -
2023 (v1)Publication
Purpose of reviewThe aim of this article is to review skin and soft tissue infections due to rapidly growing mycobacteria (RGM), with a particular focus on recently published literature (2021-2022).Recent findingsRGM are increasingly reported as a cause of skin and soft tissue infections, both in the community setting and as a cause of...
Uploaded on: February 14, 2024 -
2022 (v1)Publication
No description
Uploaded on: February 11, 2024 -
2021 (v1)Publication
No description
Uploaded on: February 14, 2024 -
2020 (v1)Publication
This article is one of ten reviews selected from the Annual Update in Intensive Care and Emergency Medicine 2020. Other selected articles can be found online at https://www.biomedcentral.com/collections/annualupdate2020. Further information about the Annual Update in Intensive Care and Emergency Medicine is available from...
Uploaded on: April 14, 2023 -
2022 (v1)Publication
Introduction Delafloxacin is a novel fluoroquinolone with peculiar characteristics such as a weak acid character, frequent in vitro activity against methicillin-resistant Staphylococcus aureus (MRSA), and a low potential for resistance selection compared with other fluoroquinolones. Areas covered The present narrative review summarizes the...
Uploaded on: October 30, 2024 -
2022 (v1)Publication
No description
Uploaded on: October 30, 2024 -
2023 (v1)Publication
IntroductionCeftolozane is a cephalosporin similar to ceftazidime in its structure, which is marketed in combination with tazobactam, a well-known & beta;-lactamase inhibitor.Areas coveredAfter a brief introduction on the drug characteristics and efficacy, we focused on available data from randomized controlled trials and post-marketing...
Uploaded on: October 30, 2024 -
2023 (v1)Publication
Purpose of review In the present narrative review, we discuss the characteristics and differences between the Infectious Diseases Society of America (IDSA) and European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines in terms on their recommendations/suggestions for the treatment of Pseudomonas aeruginosa and...
Uploaded on: October 30, 2024 -
2019 (v1)Publication
Background: Thrombocytopenia may be a dose-dependent adverse effect of linezolid therapy. Objectives: To assess whether proactive therapeutic drug monitoring (TDM) could be helpful in preventing and/or in recovering from the occurrence of linezolid-induced thrombocytopenia during long-term treatment. Methods: This was a monocentric,...
Uploaded on: April 14, 2023 -
2019 (v1)Publication
The treatment of multidrug-resistant Gram-negative bacteria (MDR-GNB) infections in critically ill patients presents many challenges. Since an effective treatment should be administered as soon as possible, resistance to many antimicrobial classes almost invariably reduces the probability of adequate empirical coverage, with possible...
Uploaded on: April 14, 2023 -
2022 (v1)Publication
Purpose of reviewTo discuss empirical therapy for severe infections due to Gram-negative bacteria with difficult-to-treat resistance (GNB-DTR) in current clinical practice, focusing in particular on the positioning of novel therapeutic agents and rapid diagnostic tests.Recent findingsThe current era of novel agents active against GNB-DTR and...
Uploaded on: February 14, 2024 -
2022 (v1)Publication
IntroductionInvasive candidiasis remains a leading cause of morbidity and mortality in various categories of patients at risk.Areas coveredStructure and mechanism of action, pharmacokinetics and pharmacodynamics, clinical studies, safety, and regulatory status of micafungin are explored in the present review, focusing on pediatric patients...
Uploaded on: February 14, 2024 -
2021 (v1)Publication
Purpose of review To discuss the current literature on novel agents for the treatment of carbapenem-resistant nonfermenting Gram-negative bacteria (NF-GNB) infections. Recent findings Some novel agents have recently become available that are expected to replace classical polymyxins as the first-line options for the treatment of...
Uploaded on: February 4, 2024 -
2021 (v1)Publication
Purpose of review To summarize the available results of primary analyses from high-quality randomized studies of either recently approved or possible future agents for the treatment of acute bacterial skin and skin structure infections (ABSSSI). Recent findings In the last 2 decades, several novel agents have been approved for the treatment of...
Uploaded on: February 11, 2024 -
2024 (v1)Publication
The clinical spectrum of invasive pulmonary aspergillosis (IPA) has expanded in recent decades. A large group of patients admitted to intensive care units (ICU) is indeed susceptible to the development of IPA. Although timely diagnosis and antifungal therapy of IPA in this expanding population is crucial to prevent IPA-related deaths, the...
Uploaded on: October 27, 2024